Ask the Experts: Optimizing the Use and Management of Immune Checkpoint Inhibitors
Launch Presentation (60 minutes) HandoutImmune checkpoint inhibition continues to evolve as standard therapy for a growing number of solid and hematologic malignancies. This educational activity will explore the growing role of immune checkpoint inhibition as standard management for less common malignancies and new updated indications. Additionally, though the number of cancer indications continues to grow, immune checkpoint inhibition remains clinically beneficial for only select patients, depending on the diagnosis. The current literature centered on identifying clinically relevant predictive biomarkers will also be reviewed.
The content for this activity is based on questions and comments from participants at a recent educational symposium on this topic.
Learning Objectives
- Discuss the current immune checkpoint inhibitors with a focus on novel agents and recent approvals.
- Evaluate the literature supporting potential predictive biomarkers associated with clinical response to immune checkpoint inhibition in patients with solid tumors.
- Examine the place in therapy of companion diagnostic testing for recommendation of immune checkpoint inhibitors.
Faculty
Christine M. Walko, Pharm.D., BCOP, FCCP, Activity Chair
Associate Member, Department of Individualized Cancer Management
Moffitt Cancer Center
Tampa, Florida
Ragini R. Kudchadkar, M.D.
Associate Professor
Winship Cancer Institute of Emory University
Associate Director Hematology/Oncology Fellowship Program
Atlanta, Georgia
Target Audience
This activity was planned to meet the educational needs of physicians, pharmacists, physician assistants, and nurse practitioners who are interested in immune checkpoint inhibitors and their role in cancer treatment.
Format
This activity features slide presentations, active learning, and questions/discussion with faculty.
Disclosures
In accordance with ACCME and ACPE Standards for Commercial Support, ASHP policy requires that all faculty, planners, reviewers, staff, and others in a position to control the content of this presentation disclose their financial relationships.
In this activity, only the individuals below have disclosed a relevant financial relationship. No other persons associated with this presentation have disclosed any relevant financial relationships.
Christine M. Walko, Pharm.D., BCOP, FCCP
- Bristol-Myers Squibb and Merck: Honoraria received for participation in the Institute for Clinical Immuno-Oncology’s Melanoma Board
Ragini R. Kudchadkar, M.D
- Array, Immunocore, Bristol-Myers Squibb: Advisory Board member
- Merck: Research funding received
Claim CE within 60 Days
Participants should claim CE credit for this home-study activity only if they have not claimed credit for the live activity.
To receive CE credit, complete the steps below within 60 days of completing the activity.
- View entire presentation and answer all polling questions.
- Click "Complete Activity" on the last slide to link to complete the assessment and evaluation.
- Verify credits were successfully transferred to CPE Monitor before the ACPE 60-day deadline by checking your NABP eProfile account.
After the 60-day deadline, ASHP will no longer be able to report credit(s).
CPE Information
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
ACPE #: 0204-000-19-404-H01-P
Release Date: May 22, 2019
Expiration Date: May 22, 2020
Activity Type: Application-based
CE Credits: 1.0 hour
Activity Fee: Free of charge
CME Information
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Society of Health-System Pharmacists designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.